China's pharmaceutical export enterprises have encountered "did not take orders" å°´å°¬

Business Club December 1st News November 29th, the reporter learned from the China Chamber of Commerce for the Import and Export of Medicines and Health Products that in October of this year, China's pharmaceutical import and export chain showed a "rare" double drop. According to Xu Ming, director of the General Affairs Department of the Chamber of Commerce, due to issues such as exchange rate and raw material price increase, the difficulties of nearly 30,000 pharmaceutical import and export companies will continue until at least the first half of next year.

According to the data, in October 2010, China's pharmaceutical imports amounted to US$1.53 billion in a single month, a decrease of 22.4% from the previous month; exports were US$3.1 billion, a decrease of 9.4%. Xu Ming said that benefiting from the implementation of medical reforms last year and the country’s 4 trillion yuan plan, pharmaceutical imports have soared, so this year's decline is also reasonable.

"It is really worth noting that this year's pharmaceutical exports are extremely difficult." Xu Ming stressed. It is reported that since June of this year, the appreciation of the renminbi against the US dollar has approached 3%, basically approaching the critical point at which corporate profits can withstand. "If during the financial crisis, pharmaceutical exporters did not receive orders, they would not dare to meet now." In addition, the EU market is affected by the debt crisis and the pharmaceutical market as a whole has shown stagflation, which also restricts the export of Chinese medicine. increase.

"Compared to the first half of this year, the large list of companies received has now been significantly reduced, and there is a trend of continued decline." A person in charge of a pharmaceutical import and export trading company told reporters that companies can now be described as internal and external troubles. "As the prices of domestic agricultural products and resource products continue to rise, the profits of pharmaceutical import and export companies have been further compressed."